Chardan Capital Downgrades Tenax Therapeutics to Neutral, Lowers Price Target to $5

Chardan Capital analyst Gautam Chukka downgrades Tenax Therapeutics (NASDAQ:TENX) from Buy to Neutral and lowers the price target from $27 to $5.